Stacia Dunson, NP
Family · Flowood, MSNPI 1689929366
Payments from drug & device makers
Across 157 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$732
- AstraZeneca$452
- Abbott$433
- Boehringer Ingelheim$306
- Lilly USA, LLC$270
- Novo Nordisk$244
- plus $708 from 17 others
What the payments were for
- Food & beverage$3,11299%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $732 |
| AstraZeneca | 21 | $452 |
| Abbott | 12 | $433 |
| Boehringer Ingelheim | 18 | $306 |
| Lilly USA, LLC | 15 | $270 |
| Novo Nordisk | 14 | $244 |
| Merck | 6 | $122 |
| Pfizer | 5 | $80 |
| Sanofi-aventis U.S. LLC | 4 | $73 |
| Ironwood Pharmaceuticals, Inc | 4 | $67 |
| Astellas Pharma US Inc | 3 | $55 |
| Krystal Biotech Inc | 2 | $47 |
| GSK | 3 | $45 |
| Cvrx, Inc. | 1 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Currax Pharmaceuticals LLC | 2 | $31 |
| Corcept Therapeutics | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Novartis | 1 | $18 |
| Exact Sciences | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| GRT US Holding, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ETERNA$163
How this compares
$3,144 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 91 | $126,587 |
| MounjaroTirzepatide | 84 | $104,021 |
| JardianceEmpagliflozin | 94 | $84,818 |
| FarxigaDapagliflozin Propanediol | 82 | $81,401 |
| RybelsusSemaglutide | 33 | $53,610 |
| LinzessLinaclotide | 47 | $51,250 |
| Tresiba Flextouch U-200Insulin Degludec | 25 | $32,765 |
| MyrbetriqMirabegron | 16 | $18,884 |
| EliquisApixaban | 16 | $18,681 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $17,386 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,678 |
| Lubiprostone | 18 | $4,400 |
| Olmesartan-Amlodipine-HctzOlmesartan/Amlodipin/Hcthiazid | 21 | $2,601 |
| Nebivolol Hcl | 50 | $2,001 |
| Potassium Chloride | 104 | $1,670 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $244 | $180,197124 claims |
| Lilly USA, LLCMounjaro | $270 | $104,02184 claims |
| Boehringer IngelheimJardiance | $306 | $84,81894 claims |
| AstraZenecaFarxiga | $452 | $81,40182 claims |
| AbbVieLinzess | $732 | $51,25047 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $45 | $23,06431 claims |
| Astellas Pharma US IncMyrbetriq | $55 | $18,88416 claims |
| PfizerEliquis | $80 | $18,68116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.
Other family in Flowood
- Maranda EversollFlowood$197K
- Ashley CocilovaFlowood$72K
- Tina GreggFlowood$20K
- Christina PerkinsFlowood$14K
- Jordan SmithFlowood$12K
- Shara BeckwithFlowood$12K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.